Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure

Journal of the Chinese Medical Association

Volumn 76, Issue 4, 2013, Pages 195-200

  Hung, Man Hsin ^a,b   Yu, Yuan Bin ^a,b   Hsiao, Liang Tsai ^a,b   Hong, Ying Chung ^a,b   Liu, Jin Hwang ^a,b   Gau, Jyh Pyng ^a,b   Chiou, Tzeon Jye ^a,b   Chen, Po Min ^a,b   Tzeng, Cheng Hwai ^a,b   Liu, Chun Yu ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Absolute lymphocyte count; Non Hodgkin's lymphoma; Response; Rituximab; Salvage treatment

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TREATMENT RESPONSE; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; SALVAGE THERAPY;

EID: 84875812990     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2012.12.003     Document Type: Article

References (28)

1. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359:613-626.
2. Akhtar S., Maghfoor I. Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1830-1831.
3. Czuczman M.S., Koryzna A., Mohr A., Stewart C., Donohue K., Blumenson L., et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005, 23:694-704.
4. Treon S.P., Agus T.B., Link B., Rodrigues G., Molina A., Lacy M.Q., et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001, 24:272-279.
5. Foran J.M., Rohatiner A.Z., Cunningham D., Popescu R.A., Solal-Celigny P., Ghielmini M., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
6. Zelenetz A.D., Abramson J.S., Advani R.H., Andreadis C.B., Byrd J.C., Czuczm M.S., et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010, 8:288-334.
7. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
8. Martín A., Conde E., Arnan M., Canales M.A., Deben G., Sancho J.M., et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93:1829-1836.
9. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010, 116:5103-5110.
10. Davis T.A., Grillo-López A.J., White C.A., McLaughlin P., Czuczman M.S., Link B.K., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135-3143.
11. + NHL: a prospective randomized HOVON trial. Blood 2008, 111:537-543.
12. Johnston A., Bouafia-Sauvy F., Broussais-Guillaumot F., Michallet A.S., Traullé C., Salles G., et al. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma 2010, 51:399-405.
13. Borgerding A., Hasenkamp J., Glass B., Wulf G., Trümper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol 2010, 89:283-289.
14. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Trneny M., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
15. Huang Y.C., Liu C.J., Liu C.Y., Pai J.T., Hong Y.C., Teng H.W., et al. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 2011, 90:1145-1151.
16. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
17. Song M.K., Chung J.S., Seol Y.M., Kim S.G., Shin H.J., Choi Y.J., et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010, 21:140-144.
18. Oki Y., Yamamoto K., Kato H., Kuwatsuka Y., Taji H., Kagami Y., et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 2008, 81:448-453.
19. Cox M.C., Nofroni I., Ruco L., Amodeo R., Ferrari A., La Verde G., et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008, 49:1745-1751.
20. Porrata L.F., Rsitow K., Inwards D.J., Ansell S.M., Micallef I.N., Johnston P.B., et al. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 2010, 24:1343-1349.
21. Porrata L.F., Ristow K., Habermann T.M., Witzig T.E., Inwards D.J., Markovic S.N. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2009, 84:93-97.
22. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837.
23. Plonquet A., Haioun C., Jais J.P., Debard A.L., Salles G., Bene M.C., et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 2007, 18:1209-1215.
24. Taylor R.P., Lindorfer M.A. Antigenic modulation and rituximab resistance. Semin Hematol 2010, 47:124-132.
25. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
26. Gleissner B., Küppers R., Siebert R., Glass B., Trümper L., Hiddemann W., et al. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. Br J Haematol 2008, 142:166-178.
27. Costa L.J., Micallef I.N., Inwards D.J., Johnston P.B., Porrata L.F., Ansell S.M. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant 2008, 41:715-720.
28. Shipp M.A. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has " high-risk" disease?. Blood 1994, 83:1165-1173.